Evaluation of efficacy and safety of Vildagliptin versus Voglibose as add-onin control of Post Prandial Blood Glucose in patients with Type 2 Diabetes Mellitus with Dual Therapy Failure - A Randomised Controlled Study - NI

Dr Mahima V0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Patient willing to give Informed Consent.
•2.Age above 18 years of either gender.
•3.Patients who are a known case of Type-II Diabetes diagnosed as per American Diabetes Association(ADA) Guidelines[5] with failure of PPBS control even on a maximum daily dose of Metformin 2gm along with Glimeperide 4mg for a period of 12 weeks or more.
•4.Raised Postprandial Blood Glucose PPBS
•morw than 180mg/dl even after dual therapy.
•5.FBS normal (80-130mg/dl) on dual therapy.
•6.HbA1c less than 10gm/dl on dual therapy.

•1.Patient with known micro and macro vascular complications of diabetes.
•2.Pregnant women and lactating mothers.
•3.Patients on any other oral hypoglycemic agent apart from metformin and glimepiride or on insulin.
•4.Patients diagnosed with Type I Diabetes.
•5.Patients with HbA1c more than 10gm/dl or other associated conditions warranting use of insulin.
•6.Patients with other co-existing medical illness like cardiac, pulmonary, renal, hepatic, pancreatic, GI or neurological disease or severe infections.
•7.Chronic alcoholics/alcohol abusers.
•8.Patients with known hypersensitivity to study medication.

发起方

Dr Mahima V